quinoxalines has been researched along with Coronary Disease in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ockene, I; Salmoirago-Blotcher, E | 1 |
| Coleman, T; Langley, TE; Lewis, S; McNeill, A; Szatkowski, L | 1 |
| Cuesta, G; Lovato, P; Lutz, MA | 1 |
| Amin, D; Bilder, G; Bostwick, J; Byan, L; Dunwiddie, C; Galczenski, H; Kasiewski, C; Leadley, R; Ly, C; Merkel, L; Myers, M; Needle, S; O'Conner, B; Page, K; Perrone, M; Persons, P; Spada, A; Wentz, T | 1 |
4 other study(ies) available for quinoxalines and Coronary Disease
| Article | Year |
|---|---|
Varenicline for smoking cessation in patients with coronary heart disease.
Topics: Benzazepines; Cardiovascular Diseases; Coronary Disease; Drug-Related Side Effects and Adverse Reactions; Humans; Quinoxalines; Smoking Cessation; Treatment Outcome; Varenicline | 2010 |
Prescribing of nicotine replacement therapy to cardiovascular disease patients in England.
Topics: Adult; Benzazepines; Bupropion; Coronary Disease; Drug Prescriptions; England; General Practice; Humans; Nicotinic Agonists; Prescription Drugs; Quinoxalines; Regression Analysis; Smoking Cessation; Smoking Prevention; Stroke; Tobacco Use Cessation Devices; Varenicline | 2012 |
Cost analysis of varenicline versus bupropion, nicotine replacement therapy, and unaided cessation in Nicaragua.
Topics: Adolescent; Adult; Aged; Benzazepines; Bupropion; Coronary Disease; Costs and Cost Analysis; Dopamine Uptake Inhibitors; Health Expenditures; Humans; Lung Neoplasms; Middle Aged; Nicaragua; Nicotinic Agonists; Outcome Assessment, Health Care; Pulmonary Disease, Chronic Obstructive; Quinoxalines; Smoking; Smoking Cessation; Stroke; Time Factors; Tobacco Use Cessation Devices; Varenicline; Young Adult | 2012 |
Restenosis following angioplasty in the swine coronary artery is inhibited by an orally active PDGF-receptor tyrosine kinase inhibitor, RPR101511A.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Animals; Coronary Disease; Enzyme Inhibitors; Protein-Tyrosine Kinases; Quinoxalines; Receptors, Platelet-Derived Growth Factor; Recurrence; Swine; Thiophenes; Time Factors; Tunica Intima; Tunica Media | 1999 |